# idiopathic pulmonary fibrosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis

> 11 upcoming FDA catalysts in idiopathic pulmonary fibrosis: nal er (TRVI) on August 2027 (primary completion); nal er (TRVI) on Aug to Nov 2027 (topline data readout); Ofev® (nintedanib, AVLN) on late 2027 (topline data readout); Vasculan® (ifetroban, CPIX) on January 2028 (primary completion); and 7 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [LTSE-2578 trial start](https://sec-api.dev/pdufa/ltse-2578) | GPCR | idiopathic pulmonary fibrosis | completed | "In June 2024, we initiated a Phase 1 clinical study of LTSE-2578, our oral small molecule antagonist that targets the lysophosphatidic acid 1 receptor ("LPA1R") for the treatment of idiopathic pulmonary fibrosis ("IPF")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1888886/000155837025006989/gpcr-20250331x10q.htm)) |
| August 14, 2025 | [TTI-101 primary completion](https://sec-api.dev/pdufa/tti-101) | TVRD | Idiopathic Pulmonary Fibrosis | completed | "NCT05671835 (Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Tvardi Therapeutics, Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05671835)) |
| Q4 2025 | [TTI-101 topline data readout](https://sec-api.dev/pdufa/tti-101) | TVRD | idiopathic pulmonary fibrosis | scheduled | "2 trial of TTI-101, for patients with idiopathic pulmonary fibrosis (IPF); topline data on track for Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_ex99-1.htm)) |
| October 1, 2025 | [GSK3915393 primary completion](https://sec-api.dev/pdufa/gsk3915393) | GSK | Idiopathic Pulmonary Fibrosis | withdrawn | "NCT06317285 (A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06317285)) |
| August 27, 2026 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | SNDX | Idiopathic Pulmonary Fibrosis | completed | "NCT06132256 (MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Syndax Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132256)) |
| Q4 2026 | [LTI-03 interim data readout](https://sec-api.dev/pdufa/lti-03) | RNTX | idiopathic pulmonary fibrosis | scheduled | "Its lead product candidate, LTI-03, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and has completed Phase 1a and Phase 1b clinical trials; the Company is currently conducting the Phase 2 RENEW trial, a multi-center, randomized, double-blind, placebo-controlled study expected to enroll approximately 120 patients across multiple global sites, with interim topline data anticipated in the fourth quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1420565/000119312526225352/rntx-20260331.htm)) |
| Oct 2026 to Jan 2027 | [Admilparant topline data readout](https://sec-api.dev/pdufa/admilparant) | BMY | Idiopathic Pulmonary Fibrosis | scheduled | "NCT06003426 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06003426)) |
| October 2026 | [Admilparant primary completion](https://sec-api.dev/pdufa/admilparant) | BMY | Idiopathic Pulmonary Fibrosis | delayed | "NCT06003426 (A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06003426)) |
| August 2027 | [Nal er primary completion](https://sec-api.dev/pdufa/nal-er) | TRVI | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07868419 (Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Trevi Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868419)) |
| Aug to Nov 2027 | [Nal er topline data readout](https://sec-api.dev/pdufa/nal-er) | TRVI | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07868419 (Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Trevi Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868419)) |
| late 2027 | [Ofev® (nintedanib) topline data readout](https://sec-api.dev/pdufa/nintedanib) | AVLN | idiopathic pulmonary fibrosis | scheduled | "the ongoing enrollment in the AURA Phase 2 trial of AP02 in patients with IPF, including the planned enrollment of 160 patients, and the expected timing of topline data in late 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540171/000119312526457053/ck0001540171-ex99_1.htm)) |
| January 2028 | [Vasculan® (ifetroban) primary completion](https://sec-api.dev/pdufa/ifetroban) | CPIX | Idiopathic Pulmonary Fibrosis | scheduled | "NCT05571059 (Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Cumberland Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05571059)) |
| Jan to Apr 2028 | [Vasculan® (ifetroban) topline data readout](https://sec-api.dev/pdufa/ifetroban) | CPIX | Idiopathic Pulmonary Fibrosis | scheduled | "NCT05571059 (Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Cumberland Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05571059)) |
| May 2028 | [Pipe-791 dose a primary completion](https://sec-api.dev/pdufa/pipe-791) | CTNM | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07284459 (Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Contineum Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284459)) |
| May to Aug 2028 | [Pipe-791 dose a topline data readout](https://sec-api.dev/pdufa/pipe-791) | CTNM | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07284459 (Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Contineum Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284459)) |
| June 2028 | [Nal er primary completion](https://sec-api.dev/pdufa/nal-er) | TRVI | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07671911 (Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Trevi Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671911)) |
| Jun to Sep 2028 | [Nal er topline data readout](https://sec-api.dev/pdufa/nal-er) | TRVI | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07671911 (Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Trevi Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671911)) |
| September 2029 | [ABBV-142 primary completion](https://sec-api.dev/pdufa/abbv-142) | ABBV | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07230288 (Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230288)) |
| Sep to Dec 2029 | [ABBV-142 topline data readout](https://sec-api.dev/pdufa/abbv-142) | ABBV | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07230288 (Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230288)) |

## Drugs

- [LTSE-2578](https://sec-api.dev/pdufa/ltse-2578) (GPCR)
- [TTI-101](https://sec-api.dev/pdufa/tti-101) (TVRD)
- [GSK3915393](https://sec-api.dev/pdufa/gsk3915393) (GSK)
- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab) (INCY)
- [LTI-03](https://sec-api.dev/pdufa/lti-03) (RNTX)
- [Admilparant](https://sec-api.dev/pdufa/admilparant) (BMY)
- [Nal er](https://sec-api.dev/pdufa/nal-er) (TRVI)
- [Ofev® (nintedanib)](https://sec-api.dev/pdufa/nintedanib) (AVLN)
- [Vasculan® (ifetroban)](https://sec-api.dev/pdufa/ifetroban) (CPIX)
- [Pipe-791 dose a](https://sec-api.dev/pdufa/pipe-791) (CTNM)
- [ABBV-142](https://sec-api.dev/pdufa/abbv-142) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "idiopathic pulmonary fibrosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis

```bibtex
@misc{secapidev_indications_idiopathic_pulmonary_fibrosis_20261116,
  title        = {idiopathic pulmonary fibrosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_idiopathic_pulmonary_fibrosis_20261116","title":"idiopathic pulmonary fibrosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
